The paper reports findings from a study that used retrospective data from a single center in Poland from 2009 to 2014. Records from a total of 104 patients, each of whom received infliximab, etanercept, or adalimumab under the National Health Fund, were assessed.
While the treatment of rheumatoid arthritis (RA) has been revolutionized by the use of biologics and biosimilars, access to these drugs is unequal among patients in higher- and lower-resource nations. In Poland, for example, only approximately 1% of patients with RA are able to access a biologic therapy.
According to a paper newly published in Reumatologica, a cost-effectiveness analysis of biologics available to treat RA can help guide decision making for countries like Poland that hope to maximize patient benefit while making judicious use of limited resources.
The paper reports findings from a study that used retrospective data from a single center in Poland from 2009 to 2014. Records from a total of 104 patients, each of whom received infliximab, etanercept, or adalimumab under the National Health Fund, were assessed. The time horizon of patient documentation spanned the time from treatment initiation to remission.
Read more about access and biologics.
The average improvement in disease activity score in a count of 28 joints was 3.30 for the infliximab group, 3.51 for the etanercept group, and 3.70 for the adalimumab group. Patients receiving all 3 therapies had a decrease in disease activity as measured by the visual analogue scale, and clinical remission was achieved by 85.29% of patients receiving adalimumab, 74.07% of those receiving etanercept, and 37.21% of those receiving infliximab.
While fewer infliximab-treated patients achieved remission, the infliximab group showed the greatest change from baseline on the health assessment questionnaire—disability index, with a drop from 1.21 to 0.76 (vs 1.59 to 1.38 for etanercept-treated patients and 1.71 to 1.53 for adalimumab-treated patients). Furthermore, after a 2-year followup period, the best quality-adjusted life-year (QALY) results were for the infliximab group; infliximab was associated with a 1.71 QALY gain, while etanercept and adalimumab were associated with QALY gains of 0.74 and 0.60, respectively.
Infliximab was also associated with the lowest average medical cost per patient, followed by etanercept. Adalimumab was associated with the highest average medical cost.
The authors of the analysis write that their findings make it easier for clinicians to decide on the most appropriate treatment for patients with RA and can help to strike the all-important balance between effective treatment and the financial sustainability of the healthcare system.
Reference
Kowalik K, Węgierska M, Barczyńska T, Jeka S. Pharmacoeconomic evaluation of treatment effectiveness with selected biologic treatment in rheumatoid arthritis therapy. Reumatologica. 2018;56(4):212-218. doi: 10.5114/reum.2018.77972.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.